Select a community
Fibromyalgia And Chronic Fatigue Syndrome
Find out more about the PatientsLikeMe
Fibromyalgia And Chronic Fatigue Syndrome Community
Home > Community Treatment Reports > Nortriptyline Treatment Report

See More Treatments

See all treatments in the PatientsLikeMe system shared by patients just like you.


Nortriptyline Treatment Report

Brand Names: Pamelor, APO-Nortriptyline

What is Nortriptyline? Nortriptyline is a tricyclic antidepressant used in the treatment of depression. Off label it is used for chronic pain, anxiety disorders, bedwetting in children, attention-deficit/hyperactivity disorder (ADHD); and as an adjunctive therapy for smoking cessation.

See more information, including instructions, precautions, side effects, and interactions.


Reasons taken

58 patients in the community are taking or have taken Nortriptyline.

Top 10 (Show all)

Dosages

Based on the patients currently taking Nortriptyline.

Top 10 (Show all)

All (Show top 10)

  3 10mg as needed 10 mg daily 20 mg daily 25 mg daily 30 mg daily 40 mg daily 50 mg daily 75 mg daily 80 mg daily 100 mg daily 150 mg daily
  1 Number of Patients: 1 12 Number of Patients: 12 7 Number of Patients: 7 3 Number of Patients: 3 4 Number of Patients: 4 3 Number of Patients: 3 8 Number of Patients: 8 1 Number of Patients: 1 1 Number of Patients: 1 3 Number of Patients: 3 2 Number of Patients: 2  

Duration

How long current patients have been taking Nortriptyline or how long patients were taking Nortriptyline before stopping.

Currently Taking Nortriptyline

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
1
6
2
10
6
6

Stopped Taking Nortriptyline

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
7
1
1
0
3
2
Why Patients Stopped Taking Nortriptyline (multiple reasons could be selected)
Reason # Patients Percentage of patients
Did not seem to work 7 50% Did not seem to work: 50%
Side effects too severe 5 36% Side effects too severe: 36%
Doctor's advice 3 21% Doctor's advice: 21%
Other 2 14% Other: 14%
Expense 1 7% Expense: 7%
Not indicated 1 7% Not indicated: 7%

Report created on November 08, 2009.